Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Stonin 1–General transcription factor IIA, 1-like readthrough (STON1-GTF2A1L)
- Target
- STON1-GTF2A1L
- Molecular classification
- Fusion gene, Transcription-related factor, Other
01
Overview
STON1-GTF2A1L readthrough refers to a fusion transcript arising from adjacent genes STON1 (stonin 1) and GTF2A1L (general transcription factor IIA, 1-like). These read-through mRNAs occur infrequently and encode chimeric protein products containing elements of both stonin 1 (a vesicle trafficking protein) and GTF2A1L (a transcription factor). The biological function and clinical significance of the fusion protein have not been determined; however, genetic variation in this region has been linked to the bilaterality of neovascular age-related macular degeneration, suggesting a potential (but as yet unconfirmed) disease role. The fusion product is not yet classified as a canonical receptor, enzyme, transporter, or other established therapeutic target, and no drugs are known to interact specifically with it. The fusion is also referenced by multiple aliases (GTF2A1L, SALF, ALF) across various genomic resources.
- Other names
- GTF2A1LGTF2A1LFALFSALF
02
Mechanism of action
Not applicable; no drugs target this molecule
03
Biological functions
UnknownPossible transcriptional regulation, given the transcription factor domain from GTF2A1L
04
Disease associations
Potential association with bilateral neovascular age-related macular degeneration (AMD) via its genetic locus; function/mechanistic role in disease is unknownOther roles speculative, as disease contribution remains to be fully elucidated
05
Safety considerations
None documented, as it is neither a therapeutic target nor linked to safety issues at present
06
Biomarkers
rs4482537 SNP within the STON1-GTF2A1L genomic region has been identified as a genetic marker for the bilaterality of neovascular AMD in genome-wide association studiesNo protein or clinical biomarkers established
Beyond the preview
Go deeper on Stonin 1–General transcription factor IIA, 1-like readthrough (STON1-GTF2A1L).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Stonin 1–General transcription factor IIA, 1-like readthrough (STON1-GTF2A1L).